Allergan plc announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.
Allergan conducted this trial to evaluate the duration of effect and safety of BOTOX® Cosmetic 40, 60, and 80 unit doses versus BOTOX® Cosmetic 20 unit dose in patients with moderate to severe glabellar lines. The primary efficacy endpoint was met and was statistically significant for BOTOX® Cosmetic 40 and 80 units versus 20 unit in 226 subjects at 24 weeks (analysis, ?1 point improvement in Facial Wrinkle Scale (FWS) from baseline assessed by Investigator at Maximum Frown).
